Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41523-021-00249-1 http://scihub22266oqcxt.onion/10.1038/s41523-021-00249-1 33833237!8032688!33833237     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33833237&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       NPJ+Breast+Cancer 2021 ; 7 (1): 39 Nephropedia Template TP {{tp|p=33833237|t=2021. Nobody dares stopping clinical research, not even COVID-19 |pdf=|usr=}}{{33833237}} gab.com Text Nobody dares stopping clinical research, not even COVID-19 JO: NPJ Breast Cancer http://www.kidney.de/pget.php?&tw=1&pmid=33833237 #FOAvip In the global health emergency caused by the COVID-19, clinical trial management has proven to be critical for the pharmaceutical industry, sponsors, and healthcare professionals. Our experience as a sponsor managing interventional oncology clinical studies has provided us with some data and insights. Though limited by sample size, our data emphasize the importance of quickly adopting measures that first prioritize patient safety and data validity, then consider contingency measures such as telemedicine, virtual medical review, and remote monitoring. Successful adaptations of healthcare and patient management in response to COVID-19 have been fundamental to ensuring continuing clinical cancer research. Twit Text FOAVip Nobody dares stopping clinical research, not even COVID-19 ????NPJ Breast Cancer http://www.kidney.de/pget.php?&tw=1&pmid=33833237 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33833237 #FOAvip English Wikipedia <ref>{{Cite pmid|33833237}}</ref> Nobody dares stopping clinical research, not even COVID-19 #MMPMID33833237 Malfettone A; Di Cosimo S; Perez-Garcia JM; Garcia A; Sampayo-Cordero M; Mina L; Herrero C; Llombart-Cussac A; Cortes J NPJ Breast Cancer 2021[Apr]; 7 (1): 39 PMID33833237show ga In the global health emergency caused by the COVID-19, clinical trial management has proven to be critical for the pharmaceutical industry, sponsors, and healthcare professionals. Our experience as a sponsor managing interventional oncology clinical studies has provided us with some data and insights. Though limited by sample size, our data emphasize the importance of quickly adopting measures that first prioritize patient safety and data validity, then consider contingency measures such as telemedicine, virtual medical review, and remote monitoring. Successful adaptations of healthcare and patient management in response to COVID-19 have been fundamental to ensuring continuing clinical cancer research. ?Nobody dares stopping clinical research, not even COVID-19 (epmc).pdf DeepDyve Pubget Overpricing